智启未来·石见新生 药石科技AI战略大会赋能生物医药智能化新变革

Core Insights - The conference held by Yaoshi Technology Group focused on the integration of AI in the pharmaceutical industry, aligning with national strategies for high-quality development and innovation in biomedicine [1][5] - The event gathered over a hundred participants, including executives and industry partners, to discuss AI's role in drug development, smart manufacturing, and CRDMO services [1][5] Group 1: Company Strategy - Dr. Yang Minmin, the founder and CEO, emphasized that AI empowerment is the core driving force for industry competition and highlighted the need for accurate data and streamlined business processes for successful transformation [3][4] - The company aims to lead sustainable development through green and intelligent chemical innovations, establishing dual platforms for smart R&D and manufacturing [3][4] Group 2: AI Implementation - The Chief Information Officer, Dr. Liu Heping, outlined a three-phase AI strategy: short-term foundation building, mid-term integration, and long-term leadership, focusing on data and AI as core components [4] - Solutions for drug development challenges were presented, including knowledge graph target validation and generative AI for molecular screening, creating a closed-loop DMTA system [4] Group 3: Industry Trends - Industry partners shared insights on AI's transformative impact across the pharmaceutical supply chain, highlighting advancements in decision-making, safety, efficiency, and cost reduction [5] - The conference established a consensus that AI transformation is essential, with a clear path for implementation focusing on data foundation, scenario prioritization, and ecosystem collaboration [5]